Table 2.

Potential Pharmacological Therapies to Reduce ASMC Migration

Therapies	Summary of findings
Corticosteroids [17, 88] • Fluticasone • Dexamethasone • Budenoside	• Fluticasone and Dexamethasone shown to inhibit PDGF-stimulated ASMC migration in vitro [17]; promote inhibitory effect of Salmeterol on PDGF-stimulated ASMC migration in vitro [17] • Treatment of asthmatics with combined Budenoside and Formoterol reduced myofibrolasts in airway submucosa [88]
Beta-Agonist [17, 88] • Salmeterol • Formoterol	• Inhibition of PDGF-stimulated ASMC migration in vitro [17] • Treatment of asthmatics with combined Budenoside and Formoterol reduced myofibrolasts in airway submucosa [88]
Adenylyl Cyclase Analogue [17] • Forkskolin	• Inhibition of PDF-induced ASMC migration in vitro [17]
PDE4 Inhibitor [87] • Cilomolast	• Inhibition of non-PDGF stimulated ASMC migration in vitro [87]
CysLT Receptor Antagonist [16] • Montelukast	• Priming effect of LTE4 on PDGF-induced ASMC migration was inhibited following treatment with Montelukast in vitro [16]
DP2/CRTH2 Receptor Antagonist [16] • BWA868C	• Inhibition of PGD2-stimulated ASMC migration in vitro [16]
PPAR Agonist [110] • Ciglitazone • 15-deoxy-D12, 14-prostaglandin J2 • WY-14643	• Inhibition of PDF-induced ASMC migration in vitro [110]